Mr. Welch has served as a member of the Ultragenyx board since April 2015. Mr. Welch serves as the chairperson of public companies Structure Therapeutics (previously known as ShouTi) and Nuvation Bio Inc and as a board director for Seagen. He served as chairperson of Avexis Inc prior to its acquisition by Novartis. Prior to these roles he served as an executive partner at Sofinnova Ventures from January 2015 through January 2018. From September 2003 until its acquisition by Roche Holdings in September 2014, Mr. Welch served as CEO and president of biotechnology company InterMune, Inc. Mr. Welch also served as chairperson of InterMune from May 2008 to September 2014. From August 2002 to January 2003, Mr. Welch served as chairperson and CEO of Triangle Pharmaceuticals, Inc. From October 2000 to June 2002, Mr. Welch served as president of the pharmaceutical division of Elan Corporation, PLC.
He holds a B.A. from the University of Miami and an M.B.A. from the University of North Carolina.